The Business Research Company's Eylea HD Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but ...

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in its Eylea biosimilar case “comes as expected by ...

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

Investing.com -- Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell 1.5% following a U.S. appeals court decision that upheld a previous ruling, effectively denying a stay on ...

Warner Bros. Discovery has halted plans to launch a $10 paywall for its B/R Sports tier, while also pulling sports and news content from the Max ad tier starting March 30. By Etan Vlessing Canada ...

“Press the ‘call’ button to speak to a specialist,” they say the ad encouraged, welcoming the user to use their Bluetooth connection to complete the upsell then and there ...

alleging the company misled investors about its pricing practices for its blockbuster drug Eylea. The lawsuit, filed in the Southern District of New York, seeks to represent investors who ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...